Correction to: Pomalidomide, bortezomib and low-dose dexamethasone in lenalidomide-refractory and proteasome inhibitor-exposed myeloma (Leukemia, (2017), 31, 12, (2695-2701), 10.1038/leu.2017.173)

P. G. Richardson; C. C. Hofmeister; N. S. Raje; D. S. Siegel; S. Lonial; J. Laubach; Y. A. Efebera; D. H. Vesole; A. K. Nooka; J. Rosenblatt; D. Doss; M. H. Zaki; A. Bensmaine; J. Herring; Y. Li; L. Watkins; M. S. Chen; K. C. Anderson

ArticleOPEN ACCESS

Correction to: Pomalidomide, bortezomib and low-dose dexamethasone in lenalidomide-refractory and proteasome inhibitor-exposed myeloma (Leukemia, (2017), 31, 12, (2695-2701), 10.1038/leu.2017.173)

Leukemia

DOI: 10.1038/s41375-018-0235-5

0Citations

7Readers

Abstract

Following the publication of this article, the authors noted that the pomalidomide dose for the additional SC cohort in Fig. 1 was incorrectly listed. The correct dose for pomalidomide in the additional SC cohort should be the maximum tolerated dose of 4 mg/day, not 2 mg/day as listed in the original Fig. 1. The authors apologize for any inconvenience caused.

Cite

CITATION STYLE

APA

Richardson, P. G., Hofmeister, C. C., Raje, N. S., Siegel, D. S., Lonial, S., Laubach, J., … Anderson, K. C. (2018, October 1). Correction to: Pomalidomide, bortezomib and low-dose dexamethasone in lenalidomide-refractory and proteasome inhibitor-exposed myeloma (Leukemia, (2017), 31, 12, (2695-2701), 10.1038/leu.2017.173). Leukemia. Nature Publishing Group. https://doi.org/10.1038/s41375-018-0235-5

Correction to: Pomalidomide, bortezomib and low-dose dexamethasone in lenalidomide-refractory and proteasome inhibitor-exposed myeloma (Leukemia, (2017), 31, 12, (2695-2701), 10.1038/leu.2017.173)

Abstract

Cite

Register to see more suggestions